

**Shirley, NY (Apr 1, 2014)** - Luitpold Animal Health, a division of Luitpold Pharmaceuticals, Inc., manufacturers of Adequan® i.m. (polysulfated glycosaminoglycan), Adequan® I.A. (polysulfated glycosaminoglycan), and Adequan® Canine (polysulfated glycosaminoglycan) provides the following supply update:

We are pleased to announce that Adequan® i.m. is available **for the US market** in both the 5 mL single dose vials and 50 mL multi-dose vials for use in horses. Adequan® is available only through your veterinarian. We apologize for any inconvenience caused by the past disruption in our supply and are working diligently to ensure we continue to meet market demand.

If you are a veterinarian and need to order Adequan® or are having difficulty getting Adequan® from your veterinarian, please call our Customer Service Department at (800) 458-0163 and we will assist you.

We encourage Adequan® users to continue to work with their veterinarians to obtain the drug and discuss the most appropriate treatment regimen for your animals.

Luitpold has established a dedicated webpage on [www.adequan.com](http://www.adequan.com) where concerned parties can register to receive future communications and updates on this matter. You may also contact our Customer Service Department at 1-800-458-0163.

Adequan® i.m. and I.A. are the only polysulfated glycosaminoglycan (PSGAG) approved by the FDA for the treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness in horses. Adequan® Canine is the only polysulfated glycosaminoglycan (PSGAG) approved by the FDA for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.

Allyn Mann, Director  
Luitpold Animal Health  
Cell Phone: 816-590-5032  
Email: [amann@adequan.com](mailto:amann@adequan.com)

There are no known contraindications to the use of intramuscular Adequan® i.m. brand Polysulfated Glycosaminoglycan in horses. Studies have not been conducted to establish safety in breeding horses. **WARNING:** Do not use in horses intended for human consumption. Not for use in humans. Keep this and all medications out of the reach of children. Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Each 5 mL contains 500 mg Polysulfated Glycosaminoglycan. Brief Summary Indications: For the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.

For the intra-articular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses. Inflammatory joint reactions and septic arthritis have been reported following administration of Adequan® I.A. Joint sepsis, a rare but potentially life threatening complication, can occur after intra-articular injection. Use only in the carpal joint of horses. Each 1 mL contains 250 mg Polysulfated Glycosaminoglycan. **WARNING:** Do not use in horses intended for human consumption. Keep this and all medications out of the reach of children. Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Adequan® Canine (polysulfated glycosaminoglycan or PSGAG) should not be used in dogs who are hypersensitive to PSGAG or who have a known or suspected bleeding disorder. It should be used with caution in dogs with renal or hepatic impairment. Possible side effects (pain at injection site, diarrhea and abnormal bleeding) were mild, transient and self-limiting. Safety studies of PSGAG in breeding, pregnant or lactating dogs have not been conducted.

See Full Prescribing Information for each ADEQUAN® product at [www.adequan.com](http://www.adequan.com). Adequan® is a registered trademark of Luitpold Pharmaceuticals, Inc. ©LUITPOLD PHARMACEUTICALS, INC., Animal Health Division, Shirley, NY 11967.

AHD011 Rev 4/2014